SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - FRA:56S1 - FR0013154002 - Common Stock
207.2 EUR
0 (0%)
We assign a fundamental rating of 4 out of 10 to 56S1. 56S1 was compared to 18 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. 56S1 is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
In the past year 56S1 had a positive cash flow from operations.
56S1 had positive earnings in each of the past 5 years.
Each year in the past 5 years 56S1 had a positive operating cash flow.
1.2 Ratios
56S1 has a worse Return On Assets (3.35%) than 66.67% of its industry peers.
56S1 has a worse Return On Equity (6.54%) than 66.67% of its industry peers.
56S1 has a Return On Invested Capital (5.94%) which is comparable to the rest of the industry.
Measured over the past 3 years, the Average Return On Invested Capital for 56S1 is above the industry average of 7.57%.
The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
With a Profit Margin value of 8.96%, 56S1 perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
In the last couple of years the Profit Margin of 56S1 has declined.
56S1's Operating Margin of 16.63% is fine compared to the rest of the industry. 56S1 outperforms 61.11% of its industry peers.
56S1's Operating Margin has declined in the last couple of years.
The Gross Margin of 56S1 (45.64%) is better than 61.11% of its industry peers.
56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 56S1 is creating some value.
Compared to 1 year ago, 56S1 has more shares outstanding
Compared to 5 years ago, 56S1 has more shares outstanding
The debt/assets ratio for 56S1 has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.45 indicates that 56S1 is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.45, 56S1 belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
56S1 has a debt to FCF ratio of 6.84. This is a slightly negative value and a sign of low solvency as 56S1 would need 6.84 years to pay back of all of its debts.
56S1's Debt to FCF ratio of 6.84 is in line compared to the rest of the industry. 56S1 outperforms 44.44% of its industry peers.
A Debt/Equity ratio of 0.50 indicates that 56S1 is not too dependend on debt financing.
The Debt to Equity ratio of 56S1 (0.50) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.45 |
ROIC/WACC0.7
WACC8.53%
2.3 Liquidity
56S1 has a Current Ratio of 1.05. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
56S1 has a Current ratio of 1.05. This is in the lower half of the industry: 56S1 underperforms 72.22% of its industry peers.
56S1 has a Quick Ratio of 1.05. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
56S1's Quick ratio of 0.50 is on the low side compared to the rest of the industry. 56S1 is outperformed by 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.11%, which is quite impressive.
The Earnings Per Share has been growing slightly by 4.19% on average over the past years.
56S1 shows a small growth in Revenue. In the last year, the Revenue has grown by 7.72%.
The Revenue has been growing by 14.05% on average over the past years. This is quite good.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
Based on estimates for the next years, 56S1 will show a very strong growth in Earnings Per Share. The EPS will grow by 22.23% on average per year.
The Revenue is expected to grow by 10.45% on average over the next years. This is quite good.
EPS Next Y27.61%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
EPS Next 5Y22.23%
Revenue Next Year9.03%
Revenue Next 2Y9.51%
Revenue Next 3Y10.23%
Revenue Next 5Y10.45%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 48.07 indicates a quite expensive valuation of 56S1.
Based on the Price/Earnings ratio, 56S1 is valued more expensive than 83.33% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. 56S1 is valued rather expensively when compared to this.
56S1 is valuated quite expensively with a Price/Forward Earnings ratio of 38.61.
Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 77.78% of the companies are valued more cheaply.
56S1 is valuated expensively when we compare the Price/Forward Earnings ratio to 22.53, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.07 | ||
| Fwd PE | 38.61 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 56S1 is valued more expensive than 83.33% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 56S1 is valued a bit more expensive than 61.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.85 | ||
| EV/EBITDA | 27.77 |
4.3 Compensation for Growth
56S1's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
56S1's earnings are expected to grow with 23.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.74
PEG (5Y)11.46
EPS Next 2Y23.83%
EPS Next 3Y23.3%
5. Dividend
5.1 Amount
56S1 has a yearly dividend return of 0.33%, which is pretty low.
56S1's Dividend Yield is slightly below the industry average, which is at 0.72.
Compared to an average S&P500 Dividend Yield of 2.38, 56S1's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
56S1 pays out 25.41% of its income as dividend. This is a sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.41%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
FRA:56S1 (10/31/2025, 7:00:00 PM)
207.2
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.17B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Analysts81.11
Price Target239.05 (15.37%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)-0.17%
PT rev (3m)-1.57%
EPS NQ rev (1m)9.76%
EPS NQ rev (3m)9.76%
EPS NY rev (1m)0%
EPS NY rev (3m)2.93%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)5.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.07 | ||
| Fwd PE | 38.61 | ||
| P/S | 6.84 | ||
| P/FCF | 53.85 | ||
| P/OCF | 27.6 | ||
| P/B | 5 | ||
| P/tB | N/A | ||
| EV/EBITDA | 27.77 |
EPS(TTM)4.31
EY2.08%
EPS(NY)5.37
Fwd EY2.59%
FCF(TTM)3.85
FCFY1.86%
OCF(TTM)7.51
OCFY3.62%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.74
PEG (5Y)11.46
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.45 |
F-Score8
WACC8.53%
ROIC/WACC0.7
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y27.61%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
EPS Next 5Y22.23%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year9.03%
Revenue Next 2Y9.51%
Revenue Next 3Y10.23%
Revenue Next 5Y10.45%
EBIT growth 1Y25.54%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year92.67%
EBIT Next 3Y37.11%
EBIT Next 5Y27.7%
FCF growth 1Y219.27%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.97%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
What is the valuation status of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
Can you provide the profitability details for SARTORIUS STEDIM BIOTECH?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 5 / 10.
What is the financial health of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The financial health rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10.
How sustainable is the dividend of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The dividend rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 3 / 10 and the dividend payout ratio is 25.41%.